Cancer immunology research · 2024
Melanoma Clonal Heterogeneity Leads to Secondary Resistance after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes.
СтатьяКлинический случайПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
König David, Sandholzer Michael T, Uzun Sarp, Zingg Andreas, Ritschard Reto, Thut Helen, Glatz Katharina, Kappos Elisabeth A, Schaefer Dirk J, Kettelhack Christoph, Passweg Jakob R, Holbro Andreas, Baur Katharina, Medinger Michael, Buser Andreas, Lardinois Didier, Jeker Lukas T, Khanna Nina, Stenner Frank, Kasenda Benjamin, Homicsko Krisztian, Matter Matthias, Rodrigues Mantuano Natalia, Zippelius Alfred, Läubli Heinz
Аннотация
Adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TIL) is effective in patients with melanoma, although long-term responses seem restricted in patients who have complete remissions. Many patients develop secondary resistance to TIL-ACT but the involved mechanisms are unclear. In this study, we describe a case of secondary resistance to TIL-ACT possibly due to intratumoral heterogeneity and selection of a resistant tumor cell clone by the transferred T cells. To the best our knowledge, this is the first case of clonal selection of a pre-existing nondominant tumor cell clone; this report demonstrates the mechanism involved in secondary resistance to TIL-ACT that can potentially change current clinical practice because it advocates for T-cell collection from multiple tumor sites and analysis of tumor heterogeneity before treatment with TIL-ACT.